SCHEMBL6352850

SCHEMBL6352850

COc1cc(S(=O)(=O)Nc2ccc3ccn(C)c3c2)cc(OC)c1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.49
HTT P42858 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 1/20 0.49
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44
TUBB6 Q9BUF5 1/20 0.44
TUBB2B Q9BVA1 1/20 0.44
TUBB1 Q9H4B7 1/20 0.44
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6343382 0.90 PKM (0.61) PKMHTTSMN1; SMN2LMNATUBB4A
SCHEMBL26792 0.81 PKM (0.61) PKMHTTSMN1; SMN2LMNATUBB4A
SCHEMBL2842158 0.80 PKM (0.53) PKMHTR6SIRT6
SCHEMBL6341064 0.79 L3MBTL1 (0.51) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL3599576 0.78 PKM (0.61) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL6339610 0.77 BRPF1 (0.53) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL6339218 0.76 L3MBTL1 (0.62) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL6343470 0.75 TUBB4A (0.53) HTTSMN1; SMN2LMNATUBB4ATUBB
SCHEMBL6341836 0.74 LMNA (0.60) PKMHTTSMN1; SMN2LMNAMAPT
SCHEMBL3590172 0.74 ALDH1A1 (0.55) PKMHTTSMN1; SMN2LMNAHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US claimed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US claimed
EP-1181269-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2002-02-27 EP claimed
WO-2000073264-A1 CELL PROLIFERATION INHIBITORS ABBOTT LABORATORIES (US) 2000-12-07 WO claimed
US-20050187246-A1 Cell proliferation inhibitors LI QUN (US) 2005-08-25 US disclosed
US-6924304-B2 Cell proliferation inhibitors ABBOTT LABORATORIES (US) 2005-08-02 US disclosed
US-20030096856-A1 Cell proliferation inhibitors ABBVIE INC. 2003-05-22 US disclosed
US-6521658-B1 Cell proliferation inhibitors ABBOTT LABORATORIES 2003-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096856-A1 Cell proliferation inhibitors MKI67, CCNI, CCNA1 PKM 1894/4885HTT 4313/4885SMN1; SMN2 1869/4885
US-20050187246-A1 Cell proliferation inhibitors MKI67, CCNI, CCNC PKM 1733/4885HTT 4031/4885SMN1; SMN2 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.